Eli Lilly (LLY) Other Non-Current Liabilities (2009 - 2026)

Eli Lilly (LLY) has reported Other Non-Current Liabilities for 18 consecutive years, with $4.1 billion the latest figure, recorded in Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $4.1 billion, up 78.51% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.1 billion (up 78.51% YoY), and the FY2025 annual result was $4.0 billion, down 2.24% from the prior year.
• Other Non-Current Liabilities was $4.1 billion for Q1 2026 at Eli Lilly, up from $4.0 billion in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $6.3 billion in Q3 2025 and troughed at $1.7 billion in Q1 2022.
• Average Other Non-Current Liabilities over 5 years is $2.8 billion, with a median of $2.3 billion recorded in 2025.
• Year-over-year, Other Non-Current Liabilities slumped 52.3% in 2022 and jumped 181.04% in 2025.
• Over 5 years, Other Non-Current Liabilities stood at $1.8 billion in 2022, then advanced by 22.84% to $2.2 billion in 2023, then soared by 81.25% to $4.1 billion in 2024, then slipped by 2.24% to $4.0 billion in 2025, then grew by 2.9% to $4.1 billion in 2026.
• Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $4.1 billion in Q1 2026, $4.0 billion in Q4 2025, and $6.3 billion in Q3 2025.